The table below shows Eterna Therapeutics Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$2.26M
-$2.06M
-$3.75M
-$6.05M
-$5.43M
-$3.43M
Capital expenditure
$2.00K
-
$101.00K
$0.00
$46.00K
$0.00
Investing cash flow
-$2.00K
-
-$97.00K
$0.00
-$46.00K
$267.00K
Dividends paid
-
-
-
-
ERNA operating cash flow (10-K history)
Eterna Therapeutics Inc. reported operating cash flow of -$7.02M for fiscal year 2025. That is up 55.7% from -$15.84M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $23.00K (FY 2016) to -$7.02M. Figures come from the company's audited annual reports as filed with the SEC.